| | | | | | | | | | |
| (125) Treatment of Metastatic and Recurrent Head and Neck Squamous Cell Carcinoma | 4.61 | Compare platinum based chemotherapy treatments according to current clinical research. | 4.66 | 31 | 8 | 1 | 0 | 1 | 41 |
| | | Define and discuss advantages/disadvantages of targeted therapy with platinum based chemotherapy. | 4.61 | 29 | 10 | 1 | 0 | 1 | 41 |
| | | Contrast PD-1 inhibitors including side effects and efficacy. | 4.59 | 28 | 11 | 1 | 0 | 1 | 41 |
| | | Describe the mechanism of action (MOA) of platinum based combination chemotherapy and review the clinical trial data in this setting to include side effects and efficacy. | 4.61 | 29 | 10 | 1 | 0 | 1 | 41 |
| | | Describe the MOA of targeted therapy in combination with platinum based chemotherapy and review the clinical trial data in this setting to include side effects and efficacy. | 4.59 | 28 | 11 | 1 | 0 | 1 | 41 |
| | | Describe MOA of PD-1 inhibitors (pembrolizumab or nivolumab) and review the clinical trial data in the 2nd-line setting to include side effects and efficacy. | 4.61 | 29 | 10 | 1 | 0 | 1 | 41 |
| | | Describe other treatment options for previously treated patients (afatinib). | 4.60 | 28 | 10 | 1 | 0 | 1 | 40 |
| Sybelle Blakey Scott PharmD BCPS | 4.79 | Was an effective presenter. | 4.79 | 36 | 5 | 0 | 0 | 1 | 42 |
| | | Demonstrated expertise in content area. | 4.81 | 37 | 4 | 0 | 0 | 1 | 42 |
| | | Used teaching methods that facilitated learning. | 4.76 | 34 | 6 | 0 | 0 | 1 | 41 |
| | | Delivered a balanced presentation free of commercial bias. | 4.81 | 37 | 4 | 0 | 0 | 1 | 42 |